BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Cytognos, S.L. - ECPv4.9.7//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cytognos, S.L.
X-ORIGINAL-URL:https://www.cytognos.com
X-WR-CALDESC:Events for Cytognos, S.L.
BEGIN:VTIMEZONE
TZID:"Europe/Paris"
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20201025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID="Europe/Paris":20201029T190000
DTEND;TZID="Europe/Paris":20201029T200000
DTSTAMP:20260425T184723
CREATED:20201019T074741Z
LAST-MODIFIED:20201113T094126Z
UID:13081-1603998000-1604001600@www.cytognos.com
SUMMARY:Webinar - Monitoring Circulating Plasma Cells in routine diagnostics in Multiple Myeloma (2020/10/29) - 7:00 PM CET
DESCRIPTION:Join this webinar with our invited speaker Paula Tabares\, PhD \n“Monitoring Circulating Plasma Cells in routine diagnostics in Multiple Myeloma” \nDo you know that the evaluation of Circulating Tumor Plasma Cells (CTPC) can have an impact on patient management? \nNext Generation Flow Cytometry (NGFC) plays an important role in diagnostics\, providing a highly sensitive method to generate reliable data of clinical relevance in different plasma cell (PC) dyscrasias. \nIn the recent years\, NGFC has been successfully used for diagnosis and monitoring in multiple myeloma (MM)\, a hematological malignancy characterized by the growth of clonal plasma cells in the bone marrow. Large cohort studied with NGFC\, also in comparison with other detection methods\, have highlighted its impact in predicting patient survival. Moreover\, recent studies showed the presence of MM tumor malignant cells in peripheral blood\, which can be detected and quantified by using NGFC\, providing additional prognostic information. \nIn this webinar\, Dr. Paula Tabares will describe the flow-based method for detection of CTPC in peripheral blood and the benefit of assessing CTPC in the clinical routine. \nPaula Tabares\, PhD\nScientist in Research and Diagnostics\nInterdisciplinary Center for Clinical Research Laboratory\nDepartment of Medicine II\, University Hospital of Würzburg\, Germany \n\nBachelor´s degree in Industrial Chemistry (2004). Universidad Tecnológica de Pereira\, Colombia.\nDoctoral degree in natural sciences (2011). University of Würzburg\, Germany.\nFrom 2012 to 2017 Dr. Tabares worked as a researcher at the group of Prof. Dr. Thomas Hünig at the University of Würzburg\, where she studied the effects of the CD28 superagonist TGN1412  on regulatory T-cells and contributed to the return of TGN1412 therapy to clinical development for the treatment of rheumatoid arthritis.\nIn 2018\, she joined the research group of Prof. Dr. Andreas Beilhack\, where she established flow cytometry based MRD and CTPC methods to evaluate tumor cells in patients with multiple myeloma (MM)\, following the EuroFlow™ guidelines. The method to detect circulating plasma cells is now for the first time incorporated into the clinical routine to monitor MM patients in Germany.\n\nIn her current research\, she investigates the phenotypic profile of cancer cells\, immune cells and cells of the tumor microenvironment in patients with multiple myeloma and solid cancers utilizing next generation flow cytometry. \n
URL:https://www.cytognos.com/event/webinar-monitoring-circulating-plasma-cells-in-routine-diagnostics-in-multiple-myeloma-2020-10-29-700-pm-cet/
CATEGORIES:Webinars
ATTACH;FMTTYPE=image/png:https://www.cytognos.com/wp-content/uploads/paula-tabares-webinar-min.png
END:VEVENT
END:VCALENDAR